Barbara E. Mahon, MD
Adjunct Professor, Epidemiology
Biography
Dr. Mahon received her MD and clinical training in pediatrics from the University of California, San Francisco and her MPH from the University of California, Berkeley. She trained in CDC’s Epidemic Intelligence Service (EIS). Dr. Mahon is deputy chief of the Enteric Diseases Epidemiology and Surveillance Branch at the Centers for Disease Control and Prevention (CDC). The branch is responsible for national surveillance for enteric diseases. It conducts epidemiologic studies of the burden, trends, and food source attribution of foodborne diseases caused by Listeria , Salmonella, and E. coli O157, among other pathogens. The branch’s work also focuses on vulnerable populations, including older adults, young children, and other groups, with the goal of creating knowledge needed to protect people by preventing disease. Dr. Mahon has a broad background in infectious disease epidemiology, having worked on foodborne diseases, vaccine-preventable diseases, and sexually transmitted diseases in academic and industry positions as well as in government.
Other Positions
- Adjunct Assistant Professor, General Pediatrics, Pediatrics, Boston University Chobanian & Avedisian School of Medicine
Websites
Education
- University of California San Francisco, MD
- University of California, Berkeley, MPH
- Harvard University, AB
Publications
- Published on 7/1/2024
McMorrow ML, Moline HL, Toepfer AP, Halasa NB, Schuster JE, Staat MA, Williams JV, Klein EJ, Weinberg GA, Clopper BR, Boom JA, Stewart LS, Selvarangan R, Schlaudecker EP, Michaels MG, Englund JA, Albertin CS, Mahon BE, Hall AJ, Sahni LC, Curns AT. Respiratory Syncytial Virus-Associated Hospitalizations in Children <5 Years: 2016-2022. Pediatrics. 2024 Jul 01; 154(1). PMID: 38841769.
Read at: PubMed - Published on 1/26/2024
Hall E, Mahon BE, Peacock G. The U.S. COVID-19 vaccination program: A look back and future directions. Vaccine. 2024 Jan 26. PMID: 38280828.
Read at: PubMed - Published on 10/27/2023
Lambrou AS, South E, Ballou ES, Paden CR, Fuller JA, Bart SM, Butryn DM, Novak RT, Browning SD, Kirby AE, Welsh RM, Cornforth DM, MacCannell DR, Friedman CR, Thornburg NJ, Hall AJ, Hughes LJ, Mahon BE, Daskalakis DC, Shah ND, Jackson BR, Kirking HL. Early Detection and Surveillance of the SARS-CoV-2 Variant BA.2.86 - Worldwide, July-October 2023. MMWR Morb Mortal Wkly Rep. 2023 Oct 27; 72(43):1162-1167. PMID: 37883327.
Read at: PubMed - Published on 10/20/2023
Regan JJ, Moulia DL, Link-Gelles R, Godfrey M, Mak J, Najdowski M, Rosenblum HG, Shah MM, Twentyman E, Meyer S, Peacock G, Thornburg N, Havers FP, Saydah S, Brooks O, Talbot HK, Lee GM, Bell BP, Mahon BE, Daley MF, Fleming-Dutra KE, Wallace M. Use of Updated COVID-19 Vaccines 2023-2024 Formula for Persons Aged =6 Months: Recommendations of the Advisory Committee on Immunization Practices - United States, September 2023. MMWR Morb Mortal Wkly Rep. 2023 Oct 20; 72(42):1140-1146. PMID: 37856366.
Read at: PubMed - Published on 10/13/2023
Fleming-Dutra KE, Jones JM, Roper LE, Prill MM, Ortega-Sanchez IR, Moulia DL, Wallace M, Godfrey M, Broder KR, Tepper NK, Brooks O, Sánchez PJ, Kotton CN, Mahon BE, Long SS, McMorrow ML. Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023 Oct 13; 72(41):1115-1122. PMID: 37824423.
Read at: PubMed - Published on 8/25/2023
Jones JM, Fleming-Dutra KE, Prill MM, Roper LE, Brooks O, Sánchez PJ, Kotton CN, Mahon BE, Meyer S, Long SS, McMorrow ML. Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023 Aug 25; 72(34):920-925. PMID: 37616235.
Read at: PubMed - Published on 5/12/2023
Silk BJ, Scobie HM, Duck WM, Palmer T, Ahmad FB, Binder AM, Cisewski JA, Kroop S, Soetebier K, Park M, Kite-Powell A, Cool A, Connelly E, Dietz S, Kirby AE, Hartnett K, Johnston J, Khan D, Stokley S, Paden CR, Sheppard M, Sutton P, Razzaghi H, Anderson RN, Thornburg N, Meyer S, Womack C, Weakland AP, McMorrow M, Broeker LR, Winn A, Hall AJ, Jackson B, Mahon BE, Ritchey MD. COVID-19 Surveillance After Expiration of the Public Health Emergency Declaration - United States, May 11, 2023. MMWR Morb Mortal Wkly Rep. 2023 May 12; 72(19):523-528. PMID: 37167154.
Read at: PubMed - Published on 10/5/2022
Simon JK, Kennedy SB, Mahon BE, Dubey SA, Grant-Klein RJ, Liu K, Hartzel J, Coller BG, Welebob C, Hanson ME, Grais RF. Immunogenicity of rVSV?G-ZEBOV-GP Ebola vaccine (ERVEBO®) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials. Vaccine. 2022 Nov 02; 40(46):6599-6606. PMID: 36208978.
Read at: PubMed - Published on 8/19/2022
Massetti GM, Jackson BR, Brooks JT, Perrine CG, Reott E, Hall AJ, Lubar D, Williams IT, Ritchey MD, Patel P, Liburd LC, Mahon BE. Summary of Guidance for Minimizing the Impact of COVID-19 on Individual Persons, Communities, and Health Care Systems - United States, August 2022. MMWR Morb Mortal Wkly Rep. 2022 Aug 19; 71(33):1057-1064. PMID: 35980866.
Read at: PubMed - Published on 6/24/2022
Gold JAW, Kelleher J, Magid J, Jackson BR, Pennini ME, Kushner D, Weston EJ, Rasulnia B, Kuwabara S, Bennett K, Mahon BE, Patel A, Auerbach J. Dispensing of Oral Antiviral Drugs for Treatment of COVID-19 by Zip Code-Level Social Vulnerability - United States, December 23, 2021-May 21, 2022. MMWR Morb Mortal Wkly Rep. 2022 Jun 24; 71(25):825-829. PMID: 35737571.
Read at: PubMed
View 116 more publications: View full profile at BUMC